the numbers of shares outstanding will play a roll combined with projected revenues on 150,000 users in a 1.5 million potential base of people with migranes that throw up.
but alas, it is the FDA and one can't ever predict exactly what they will do.
all I can ask is why would not they? If a small % of the people have a minor adverse affect they just dont use it.
that said, still can't predict what the FDA will do but if they do, path could go a lot higher than it is today.
my sentiment is dont buy it if you cant afford the risk.
or buy some if you can but not too much cause nobodynosenuttin.
I don't see upon approval.A run to $6-10 though.But,after approval,we probably see a partnership come into play,which will boost the stock price further.The strengths of this BoD is partnerships.Once production and sales begin,this could head to the $30 mark.Very few shares are in play.This could run for 6 months.Armando Anido wasn't brought in as CEO thinking this could fail,and he'd be the overseer of another 2-3 years of trials.His strength is in sales.You're not hearing any negativity about this product or this company.That usually means they have all their ducks in a row.